Immunocore Funding: $665M Raised, Series C (2021)

Immunocore funding overview

Immunocore is based in Abingdon, United Kingdom. Immunocore has raised $665M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series C announced in January 2021. The round record for Immunocore runs through 2021; nothing later has been disclosed. Investors on record include BlackRock, Oxford Finance, ROB Perez, Bill & Melinda Gates Foundation, CCB International, ELI Lilly And Company and 7 others. 13 distinct backers are named across the disclosed rounds.

Immunocore at a glance

Total raised: $665M
Latest round: Series C
Latest round date: January 2021
Headquarters: Abingdon, United Kingdom
Notable investors: BlackRock, Oxford Finance, ROB Perez, Bill & Melinda Gates Foundation, CCB International, ELI Lilly And Company, JDRF T1D Fund, Rock Springs Capital

Frequently asked about Immunocore funding

How much has Immunocore raised?: Immunocore has raised $665M in total disclosed funding across the rounds on record.
Who has invested in Immunocore?: BlackRock, Oxford Finance, ROB Perez, Bill & Melinda Gates Foundation, CCB International, ELI Lilly And Company are named among the investors backing Immunocore.
What was the latest Immunocore funding round?: The most recent disclosed round is a Series C, announced in January 2021.
Where is Immunocore based?: Immunocore is based in Abingdon, United Kingdom.
When did Immunocore last raise?: The last disclosed Immunocore round closed in January 2021 at Series C.

We update the Immunocore record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Abingdon and their backers are listed below.

Immunocore Funding: $665M Raised, Series C (2021)

Immunocore funding overview

Immunocore at a glance

Frequently asked about Immunocore funding

Companies related to Immunocore (22)

Browse related funding lists (5)